BioVector® LUHMES 人多巴胺能神经元前体细胞系 / BioVector® LUHMES Human Dopaminergic Neuronal Precursor Cell Line

通用定义 / General Definition:BioVector® LUHMES（Lund Human Mesencephalic）是一种源自人类中脑（Mesencephalon）的多巴胺能神经元前体细胞系。该细胞系通过 v-myc 基因的四环素受控表达实现永生化。LUHMES 的核心优势在于其高度的可塑性：在添加特定因子（如 GDNF 和 dibutyryl cAMP）并下调 v-myc 表达后，它们可以迅速、高效地分化为具有成熟电生理活性的多巴胺能神经元。它是研究帕金森病（PD）、神经毒理学、多巴胺代谢及神经保护药物筛选的理想人源细胞模型。

BioVector® LUHMES (Lund Human Mesencephalic) is a human dopaminergic neuronal precursor cell line derived from the human mesencephalon. The line was immortalized via the tetracycline-regulated expression of the v-myc oncogene. The primary advantage of LUHMES is its high plasticity: upon treatment with specific factors (such as GDNF and dibutyryl cAMP) and the downregulation of v-myc, these cells differentiate rapidly and efficiently into dopaminergic neurons with mature electrophysiological properties. It is a premier human model for studying Parkinson's Disease (PD), neurotoxicology, dopamine metabolism, and neuroprotective drug screening.

BioVector® LUHMES 技术说明书 (Technical Datasheet)

中文版说明书 (Chinese Datasheet)

1. 产品基本信息

• 产品名称： BioVector® LUHMES 人中脑神经前体细胞

• 组织来源： 人胚胎中脑 (Human Embryonic Mesencephalon)

• 生长特性： 贴壁生长（需包被）

• 分化潜能： 可诱导分化为成熟多巴胺能神经元（表达抗酪氨酸羟化酶 TH）

• 细胞形态： 增殖期呈双极性或小多角形；分化后具有长神经突起

2. 培养条件

• 基础培养基： BioVector® Advanced DMEM/F12 培养基。

• 关键添加剂（增殖期）： N2 补充剂、重组人碱性成纤维细胞生长因子 (bFGF) 以及四环素或强力霉素（用于维持 v-myc 表达）。

• 包被要求： 培养皿必须使用 多聚鸟氨酸 (Poly-L-ornithine) 和 纤连蛋白 (Fibronectin) 进行预包被。

• 培养环境： 37 摄氏度，5% $CO_2$

• 分化诱导： 移除 bFGF 并添加四环素（关闭 v-myc）、cAMP 和 GDNF，诱导 6-10 天。

3. 细胞应用

• 疾病建模： 利用 MPP+ 或 6-OHDA 诱导损伤，模拟帕金森病神经元变性。

• 神经毒理学： 评估环境毒素或化学品对人源神经元的发育毒性。

• 多巴胺研究： 探索多巴胺转运体 (DAT) 功能及突触传递机制。

4. 注意事项

• 包被质量： LUHMES 细胞对贴壁要求极高，包被不均匀会导致细胞分化失败或成团脱落。

• 血清限制： 建议使用无血清培养体系，以保持其神经前体特性并控制分化方向。

English Datasheet

1. General Product Information

• Product Name: BioVector® LUHMES Human Mesencephalic Precursor Cell Line

• Tissue Source: Human Embryonic Mesencephalon

• Growth Properties: Adherent (Requires coating)

• Differentiation Potential: Efficiently differentiates into mature dopaminergic neurons (TH-positive).

• Morphology: Bipolar or small polygonal in proliferative phase; extensive neurite outgrowth post-differentiation.

2. Culture Conditions

• Basal Medium: BioVector® Advanced DMEM/F12 Medium.

• Key Supplements (Proliferation): N2 supplement, recombinant human bFGF, and Tetracycline/Doxycycline (to maintain v-myc expression).

• Surface Coating: Plates must be pre-coated with Poly-L-ornithine and Fibronectin.

• Incubation: 37 degrees Celsius, 5% $CO_2$.

• Differentiation Protocol: Removal of bFGF and addition of Tetracycline (to shut down v-myc), cAMP, and GDNF for 6–10 days.

3. Applications

• Disease Modeling: Simulating Parkinson's disease-associated neurodegeneration using MPP+ or 6-OHDA.

• Neurotoxicology: Assessing the developmental or acute neurotoxicity of environmental toxins on human-derived neurons.

• Dopaminergic Biology: Investigating Dopamine Transporter (DAT) kinetics and synaptogenesis.

4. Key Usage Notes

• Coating Consistency: LUHMES cells are highly sensitive to the substrate; inconsistent coating leads to poor attachment and failed neuronal maturation.

• Serum-Free Requirement: BioVector® recommends strictly serum-free conditions to prevent uncontrolled differentiation and maintain the integrity of the precursor pool.

注意 / Note: BioVector® LUHMES 细胞系应在生物安全二级 (BSL-2) 条件下操作。分化后的神经元为终末分化状态，不再具有增殖能力，因此实验设计需精确计算初始接种密度。

BioVector® LUHMES should be handled under Biosafety Level 2 (BSL-2). Differentiated neurons are post-mitotic and cannot be subcultured; precise initial seeding density is critical for successful experimental design.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

E-mail: BioVector@163.com

http://www.biovector.net